Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 19, 2026, 5:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Gefitinib Clear all
Active, not recruiting Phase 2 Interventional

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

NCT03944772
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Osimertinib, Savolitinib, Gefitinib, Necitumumab, Durvalumab, Carboplatin, Pemetrexed, Alectinib, Selpercatinib, Selumetinib, Etoposide, Cisplatin, Datopotamab deruxtecan
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
16
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Sep 19, 2026, 5:04 PM EDT
Completed Phase 1 Interventional

Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer

NCT01967095
View directory record Official record
Conditions
EGFR-Mutant Lung Cancer
Interventions
erlotinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2018 · Synced Sep 19, 2026, 5:04 PM EDT
Terminated Phase 2 Interventional

Trial of ZD1839 (Iressa) and Tamoxifen in Breast Cancer Patients

NCT00206492
View directory record Official record
Conditions
Breast Cancer
Interventions
Iressa, Tamoxifen
Drug
Lead sponsor
Baylor Breast Care Center
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Sep 19, 2026, 5:04 PM EDT
Completed Phase 2 Interventional

Gefitinib and Celecoxib in Treating Patients With Refractory Non-Small Cell Lung Cancer

NCT00068653
View directory record Official record
Conditions
Lung Cancer
Interventions
Celecoxib, ZD1839
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 28, 2013 · Synced Sep 19, 2026, 5:04 PM EDT
Terminated Phase 1 Interventional

Gefitinib, Cisplatin, Irinotecan, and Radiation Therapy Before Surgery in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery

NCT00290719
View directory record Official record
Conditions
Esophageal Cancer
Interventions
cisplatin, gefitinib, irinotecan hydrochloride, conventional surgery, neoadjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Sep 19, 2026, 5:04 PM EDT
Completed Phase 2 Interventional Results available

Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer

NCT00126555
View directory record Official record
Conditions
Recurrent Skin Cancer, Squamous Cell Carcinoma of the Skin
Interventions
Gefitinib, Radiotherapy, Conventional surgery, laboratory biomarker analysis
Drug · Radiation · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 29, 2019 · Synced Sep 19, 2026, 5:04 PM EDT
Completed Phase 1Phase 2 Interventional

A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung Cancer

NCT00238628
View directory record Official record
Conditions
Lung Cancer
Interventions
Bexarotene, Iressa
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 19, 2026, 5:04 PM EDT
Completed Phase 3 Interventional

Iressa Expanded Access Program (EAP)

NCT00034879
View directory record Official record
Conditions
Carcinoma, Non-small-cell Lung, Metastases, Neoplasm
Interventions
ZD1839 (Gefitinib)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
626
States / cities
Alabaster, Alabama • Anniston, Alabama • Birmingham, Alabama + 623 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Sep 19, 2026, 5:04 PM EDT
Completed Phase 1 Interventional

Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma

NCT00027625
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
gefitinib, temozolomide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Bethesda, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Sep 19, 2026, 5:04 PM EDT
Completed Phase 2 Interventional

Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors

NCT00025675
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
gefitinib
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Bethesda, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Sep 19, 2026, 5:04 PM EDT
Completed Phase 1 Interventional

Gefitinib in Treating Children With Refractory Solid Tumors

NCT00040781
View directory record Official record
Conditions
Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
gefitinib, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2013 · Synced Sep 19, 2026, 5:04 PM EDT
Completed Phase 2 Interventional Results available

ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin

NCT00054691
View directory record Official record
Conditions
Skin Cancer
Interventions
Iressa
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2015 · Synced Sep 19, 2026, 5:04 PM EDT
Completed Phase 2 Interventional

Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian Cancer

NCT00181688
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Carcinoma, Tubal Carcinoma
Interventions
Iressa (ZD1839), Arimidex (Anastrozole)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 4, 2012 · Synced Sep 19, 2026, 5:04 PM EDT
Terminated Phase 2 Interventional Results available

Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer

NCT00479089
View directory record Official record
Conditions
Bladder Cancer
Interventions
Docetaxel, ZD1839, Dexamethasone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2015 · Synced Sep 19, 2026, 5:04 PM EDT
Completed Phase 1 Interventional

A Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

NCT00162318
View directory record Official record
Conditions
Non-Small-Cell Lung Carcinoma
Interventions
Cetuximab + Gefitinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 27, 2015 · Synced Sep 19, 2026, 5:04 PM EDT
Completed Phase 2 Interventional

Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer

NCT00100945
View directory record Official record
Conditions
Esophageal Cancer
Interventions
gefitinib
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
119
States / cities
Mobile, Alabama • Jacksonville, Florida • Aurora, Illinois + 77 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2016 · Synced Sep 19, 2026, 5:04 PM EDT
Completed Phase 2 Interventional Results available

Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene

NCT00588445
View directory record Official record
Conditions
Lung Cancer, Non-small Cell Lung Cancer, Bronchioloalveolar Cancer
Interventions
Gefitinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 21, 2016 · Synced Sep 19, 2026, 5:04 PM EDT
Completed Phase 2 Interventional

Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC)

NCT00215202
View directory record Official record
Conditions
Nonresectable Adrenocortical Carcinoma
Interventions
Iressa (ZD1839)
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
4
States / cities
Louisville, Kentucky • Boston, Massachusetts • Lebanon, New Hampshire + 1 more
Source: ClinicalTrials.gov public record
Updated May 16, 2018 · Synced Sep 19, 2026, 5:04 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Cisplatin, Fluorouracil, Iressa, and Radiation Therapy Patients With Locally Advanced Head and Neck Cancer

NCT00352105
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
cisplatin, fluorouracil, Iressa, hyperfractionated radiation therapy
Drug · Radiation
Lead sponsor
David Adelstein
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 4, 2012 · Synced Sep 19, 2026, 5:04 PM EDT
Completed Phase 1 Interventional Results available

Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)

NCT02157883
View directory record Official record
Conditions
Advanced Non Small Cell Lung Cancer, Advanced (Inoperable) Non Small Cell Lung Cancer
Interventions
Pharmacokinetic sampling, AZD9291, Itraconazole
Procedure · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
2
States / cities
San Diego, California • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Sep 19, 2026, 5:04 PM EDT
Completed Phase 3 Interventional

Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX)

NCT00206219
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Gefitinib, methotrexate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
26
States / cities
Birmingham, Alabama • Tucson, Arizona • Palm Springs, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2011 · Synced Sep 19, 2026, 5:04 PM EDT
Completed Phase 2 Interventional

Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00029003
View directory record Official record
Conditions
Bronchoalveolar Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
gefitinib, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 27, 2013 · Synced Sep 19, 2026, 5:04 PM EDT
Terminated Phase 2 Interventional Results available

Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib

NCT01189435
View directory record Official record
Conditions
Lung Cancer
Interventions
erlotinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Sep 19, 2026, 5:04 PM EDT
Completed Phase 2 Interventional

ZD 1839 in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck

NCT00015964
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
ZD1839
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
11
States / cities
Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced Sep 19, 2026, 5:04 PM EDT